Cellipont Bioservices, a contract development and manufacturing organization (CDMO), entered into an agreement with Diakonos Oncology for the process development and cGMP manufacturing of DOC1021, an autologous dendritic cell vaccine being manufactured for the treatment of glioblastoma multiforme (GBM) and other cancer indications. With a first of its kind approach, Diakonos’ DOC1021 activates a natural anti-viral immune response against a patient’s tumor. Due to the promising res...